𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A mechanism for the hydrolytic deamination of cytosine arabinoside in aqueous buffer

✍ Scribed by Robert E. Notari


Publisher
John Wiley and Sons
Year
1967
Tongue
English
Weight
544 KB
Volume
56
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


A kinetic approach for the mechanism of
✍ T. Mushinga; S. B. Jonnalagadda πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 416 KB

The oxidation kinetics of malachite green (MG) with peroxydisulphate ion (PDS) were investigated by monitoring the absorbance change at 618 nm, in aqueous solutions under buffered and unbuffered conditions. Under both conditions, the reaction had first order dependence on reductant and a fractionah&

Etoposide in combination with intermedia
✍ Dr J. S. Whelan; C. L. Davis; A. Z. S. Rohatiner; M. Leahy; P. K. Maccallum; R. πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 510 KB

Thirty-four patients with refractory or recurrent high grade non-Hodgkin's lymphoma (NHL) or acute leukemia were treated with a combination of etoposide, 100 mg/mZ daily, and ara C, 1 g/m2 twice daily, for 5 days (VPARAC). This therapy was given in the anticipation that remissions thus achieved woul

A mechanism for the habit modification o
✍ Dr. R. J. Davey; Prof. J. W. Mullin πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 English βš– 313 KB πŸ‘ 1 views

## Abstract Ammonium dihydrogen phosphate (ADP) crystals develop new high index faces when grown from aqueous solution containing up to 1000 ppm of added CrCl~3~ Β· 6 H~2~O. The crystallographic nature of these faces has been studied as a function of the CrCl~3~ Β· 6 H~2~O concentration in the growth

The treatment of acute lymphoblastic leu
✍ Rothwell, Miss D. πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 439 KB

## Abstract In a comparison of treatments for standard‐risk acute lymphoblastic leukaemia in children (UKALL III), there were no differences in remission lengths between regimens with or without second‐line drugs (cytosine arabinoside and asparaginase) and with continuous or discontinuous mercaptop